StockStory.org on MSN3d
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...
Vertex Pharmaceuticals price target raised to $459 from $450 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...
The Boston Globe12d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...